ANIP
Price
$79.14
Change
-$0.10 (-0.13%)
Updated
Aug 3, 12:22 PM (EDT)
Capitalization
1.8B
9 days until earnings call
Intraday BUY SELL Signals
EOLS
Price
$5.84
Change
-$0.17 (-2.83%)
Updated
Jul 31 closing price
Capitalization
384.59M
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIP vs EOLS

ANIP vs EOLS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANIP vs. EOLS commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and EOLS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (ANIP: $79.24 vs. EOLS: $5.84)
Brand notoriety: ANIP and EOLS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIP: 52% vs. EOLS: 54%
Market capitalization -- ANIP: $1.8B vs. EOLS: $384.59M
ANIP [@Pharmaceuticals: Generic] is valued at $1.8B. EOLS’s [@Pharmaceuticals: Generic] market capitalization is $384.59M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 0 FA rating(s) are green whileEOLS’s FA Score has 0 green FA rating(s).

  • ANIP’s FA Score: 0 green, 5 red.
  • EOLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ANIP is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 3 TA indicator(s) are bullish while EOLS’s TA Score has 5 bullish TA indicator(s).

  • ANIP’s TA Score: 3 bullish, 6 bearish.
  • EOLS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than ANIP.

Price Growth

ANIP (@Pharmaceuticals: Generic) experienced а +2.05% price change this week, while EOLS (@Pharmaceuticals: Generic) price change was -2.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.97%. For the same industry, the average monthly price growth was -4.92%, and the average quarterly price growth was +21.09%.

Reported Earning Dates

ANIP is expected to report earnings on Aug 12, 2026.

EOLS is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.97% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($1.8B) has a higher market cap than EOLS($385M). ANIP YTD gains are higher at: 0.380 vs. EOLS (-12.180). ANIP has higher annual earnings (EBITDA): 224M vs. EOLS (-13.7M). ANIP has more cash in the bank: 326M vs. EOLS (49.8M). EOLS has less debt than ANIP: EOLS (165M) vs ANIP (614M). ANIP has higher revenues than EOLS: ANIP (924M) vs EOLS (302M).
ANIPEOLSANIP / EOLS
Capitalization1.8B385M468%
EBITDA224M-13.7M-1,635%
Gain YTD0.380-12.180-3%
P/E Ratio20.27N/A-
Revenue924M302M306%
Total Cash326M49.8M655%
Total Debt614M165M372%
FUNDAMENTALS RATINGS
ANIP vs EOLS: Fundamental Ratings
ANIP
EOLS
OUTLOOK RATING
1..100
503
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
52100
PRICE GROWTH RATING
1..100
5559
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EOLS's Valuation (80) in the Pharmaceuticals Major industry is in the same range as ANIP (84) in the Pharmaceuticals Other industry. This means that EOLS’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that ANIP’s stock grew somewhat faster than EOLS’s over the last 12 months.

ANIP's SMR Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that ANIP’s stock grew somewhat faster than EOLS’s over the last 12 months.

ANIP's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as EOLS (59) in the Pharmaceuticals Major industry. This means that ANIP’s stock grew similarly to EOLS’s over the last 12 months.

ANIP's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that ANIP’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPEOLS
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
72%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
68%
MACD
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
68%
Bearish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
73%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ANIP
Daily Signal:
Gain/Loss:
EOLS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IREZ16.251.05
+6.91%
Tradr 2X Short Iren Daily ETF
FSGS32.550.02
+0.07%
First Trust SMID Growth Strength ETF
PVI24.83-0.01
-0.06%
Invesco Floating Rate MunicipalIncomeETF
IAI186.26-0.63
-0.34%
iShares US Broker-Dealers&Secs Exchs ETF
HSCZ42.75-0.27
-0.63%
iShares Currency Hdgd MSCI EAFE SmCp ETF